Autonomix Medical wins new US patent for feedback-guided precision neuromodulation systems

AMIX•2026-08-26

Patent filing history

The patent traces to a continuation application linked to filings from 2012 and 2014.

Claims include tumor-focused applications

Claims include tumor-focused applications using therapeutic fluid to effect neural ablation aimed at reducing cancer pain.

Patent grant covers feedback-guided precision neuromodulation systems

Autonomix Medical secured U.S. Patent No. 12,714,780, issued Aug. 25, 2026, covering feedback-guided precision neuromodulation systems.

Protection covers real-time physiological feedback to control therapy delivery, including sensing and imaging to guide treatment based on tissue response.

Autonomix Medical wins new US patent for feedback-guided precision neuromodulation systems

Patent filing history

Claims include tumor-focused applications

Patent grant covers feedback-guided precision neuromodulation systems

Related News

Kodiak AI partners with AMD to use EPYC processors in seventh-generation autonomous truck platform

SentinelOne-Tenable research finds cyber attackers target edge-device vendor ecosystems over individual CVEs

AeroVironment wins USD 51 million US Army order for Switchblade 600 systems

Smith-Midland wins $2.2 million SlenderWall contract for U.S. Coast Guard clinic project in Charleston, South Carolina

US inflation remains sticky in July; 2nd-quarter GDP unrevised at 1.5%